Compare Cassava Sciences Inc (FLNA) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Schwab US Dividend Equity ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Schwab US Dividend Equity ETF trades at $33.08 (market cap $108.68B). The key difference: Schwab US Dividend Equity ETF is far larger — about 2758.4× Cassava Sciences Inc's market cap, and Schwab US Dividend Equity ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Schwab US Dividend Equity ETF for 62 Days on average.
| FLNA | SCHD | |
|---|---|---|
Market Cap | $39.40M | $108.68B |
Volume | 759,018 | 21,463,071 |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $35.21 |
52-Week Low | $0.68 | $26.44 |
Typical Hold Time | 37 Days | 62 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
SCHD trades at $32.65, down 0.61% on the day, with a bearish technical signal driven by moving averages. The ETF has outperformed the S&P 500 in 2026, with dividend growth attracting income investors. Recent news highlights its defensive tilt and quality focus amid a market pullback.
Outlook is mixed: strong dividend appeal and low fees support long-term income, but technical weakness and interest rate sensitivity pose near-term risks. Investors should weigh SCHD's consistent payout growth against potential underperformance in rising rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
